Viatris Viagra ® — Net Sales decreased by 8.8% to $95.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 3.6%, from $98.50M to $95.00M. Over 4 years (FY 2021 to FY 2025), Viagra ® — Net Sales shows a downward trend with a -6.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests strong brand loyalty or successful lifecycle management, while a decrease may indicate increased generic competition or market saturation.
This metric represents the total revenue generated from the sale of a specific branded pharmaceutical product after acco...
Similar to legacy brand revenue metrics reported by other large-cap pharmaceutical companies for off-patent or mature specialty products.
vtrs_segment_viagra_net_sales| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $134.80M | $138.00M | $121.40M | $129.80M | $115.10M | $117.00M | $97.00M | $115.00M | $111.00M | $110.50M | $92.30M | $100.70M | $106.10M | $100.20M | $88.60M | $98.50M | $100.30M | $105.20M | $104.20M | $95.00M |
| QoQ Change | — | +2.4% | -12.0% | +6.9% | -11.3% | +1.7% | -17.1% | +18.6% | -3.5% | -0.5% | -16.5% | +9.1% | +5.4% | -5.6% | -11.6% | +11.2% | +1.8% | +4.9% | -1.0% | -8.8% |
| YoY Change | — | — | — | — | -14.6% | -15.2% | -20.1% | -11.4% | -3.6% | -5.6% | -4.8% | -12.4% | -4.4% | -9.3% | -4.0% | -2.2% | -5.5% | +5.0% | +17.6% | -3.6% |